造血干细胞移植后淋巴细胞增殖性疾病的诊治  

Diagnosis and management of post-transplant lymphoproliferative disorders

作　　者：许兰平[1] 

机构地区：[1]北京大学人民医院血液病研究所,北京100044

出　　处：《中国实用内科杂志》2010年第11期1059-1060,共2页Chinese Journal of Practical Internal Medicine

基　　金：国家杰出青年科学基金(30725083);教育部创新团队发展计划项目(IRT0702);卫生部公益专项基金(200802027)

摘　　要：移植后淋巴细胞增殖性疾病(post-transplant lymphoproliferative disorders,PTLD)是造血干细胞移植后(hematopoietic stem celltransplantation,HSCT)严重的并发症之一,发病多数与Epstein-Barr病毒感染有关,可以表现为多种形式的临床表现和病理类型。因早期PTLD进展迅速、病死率极高,需要临床医生及时做出诊断。本文就HSCT后PTLD流行病学、发病机制、临床表现及诊治方面的最新进展做一概述。Post-transplant lymphoproliferative disorders （PTLD） is one of the most potentially life-threatening complications after hematopoietic stem cell transplantation, and is mostly associated with Epstein-Barr virus （EBV） infection. PTLD may have a wide range of clinical manifestations and pathological classifications. The rap- id progression and high fatality of early PTLD should prompt clinicians to a timely diagnosis. This paper presents a review of the latest update on epidemiology, pathogenesis,clinical manifestations,diagnosis and management of post-HSCT PTLD.

关 键 词：造血干细胞移植 淋巴细胞增殖性疾病 

分 类 号：R5[医药卫生—内科学]